Bladder cancer (BC) is the fifth most common cancer worldwide and is associated with significant morbidity and mortality. The prognosis of muscle invasive BC is poor, and recurrence is common after radical surgery or chemotherapy. Therefore, new diagnostic methods and treatment modalities are critical. MicroRNAs (miRNAs), a class of small noncoding RNAs, regulate the expression of protein-coding genes by repressing translation or cleaving RNA transcripts in a sequence-specific manner. miRNAs have important roles in the regulation of genes involved in cancer development, progression, and metastasis. The availability of genomewide miRNA expression profiles by deep sequencing technology has facilitated rapid and precise identification of aberrant miRNA expression in BC. Indeed, several miRNAs that are either upregulated or downregulated have been shown to have associations with significant cancer pathways. Furthermore, many miRNAs, including those that can be detected in urine and blood, have been studied as potential noninvasive tumor markers for diagnostic and prognostic purposes. Here, we searched PubMed for publications describing the role of miRNAs in BC by using the keywords "bladder cancer" and "microRNA" on March 1, 2016. We found 374 papers and selected articles written in English in which the level of scientific detail and reporting were sufficient and in which novel findings were demonstrated. In this review, we summarize these studies from the point of view of miRNA-related molecular networks (specific miRNAs and their targets) and miRNAs as tumor markers in BC. We also discuss future directions of miRNA studies in the context of therapeutic modalities.
INTRODUCTION
Bladder cancer (BC) is one of the leading causes of can cerrelated death worldwide, with an estimated 429,800 new cases and 165,100 deaths globally in 2012 [1] . BCs can be categorized into 2 groups: nonmuscle invasive BC (NMIBC) and muscle invasive BC (MIBC). Approximately 70% to 80% of patients are diagnosed with NMIBC, and some of these patients have a high risk of recurrence and a variable risk of progression despite administration of local therapies [2] . The remaining 25% of patients with MIBC are managed miRNAs in bladder cancer low sensitivity of urinary cytology, patients are still forced to undergo a painful cystoscopic procedure to confirm the initial diagnosis and to check for recurrence during followup examinations after undergoing transurethral resection of bladder tumors. Several new urinebased tests for BC, such as bladder tumor antigen, nuclear matrix protein 22 (NMP22, Sysmex Corp., Kobe, Japan), and FISH (UroVysion, Abbott Molecular Inc, Des Plaines, IL, USA), have been approved for clinical use. However, these new urinary markers have not been widely applied because they have relatively low specificities (60%-80%) compared with urinary cytology, despite their higher sensitivities (50%-70%) [3] . Thus, specificity may come at the cost of sensitivity, and conventional urinary cytology is a good example of this compromise. Accordingly, new effective diagnostic markers are urgently needed for patients with BC.
MicroRNAs (miRNAs) are endogenous small noncoding RNA molecules (19) (20) (21) (22) bases in length) that negatively regulate the expression of proteincoding genes in a se quencespecific manner [4] . The nature of miRNAs is unique in that one miRNA can regulate multiple proteincoding RNAs. Bioinformatics predictions have indicated that miRNAs regulate 30% to 60% of the proteincoding genes in the human genome [5, 6] . Growing evidence has demonstrated that aberrantly expressed miRNAs can act as oncogenes or tumor suppressors in various types of malignancies [7] . These miRNAs can disrupt tightly controlled RNA networks in cancer cells [8] . Since 2006, we have rigorously investigated the molecular networks of miRNAs and their target genes in clinical BC. Identification of aberrantly expressed miRNAs in BC could provide important clues for the investigation of novel molecular mechanisms of initiation, progression, and metastasis in BC. In this review, we discuss the role of miRNAs in BC on the basis of uptodate results from our laboratory and other research groups.
CURRENT CONSENSUS OF EPIGENETIC GENE REGULATION BY NONCODING RNA
After the completion of the Human Genome Project in 2003, about 20,000 to 25,000 genes were identified, and the sequences of 3 billion base pairs of human DNA were de termined [9] . Surprisingly, only 2% of the human genome encodes functional proteins; 50% to 75% of the human genome is transcribed, and 98% of the transcripts are not translated into protein. Fig. 1 shows the current consensus of epigenetic regulation by noncoding RNAs transcribed from approximately 70% of the genomic region that used to be considered as "junk DNA" [10] . These noncoding RNAs can be roughly classified into two groups according to size. The first group includes short RNAs of less than 200 nucleotides (nt) in length; miRNAs, which are small RNA molecules of around 18 to 22 nt in length, fit into this group, as do other classes of small RNAs, such as piwiinteracting RNAs (around 23-30 nt) [11] . The other group includes long noncoding RNAs (lncRNAs) of around 200 nt or more. lncRNAs have been implicated in a range of developmental processes and diseases and can inhibit or activate gene expression through a range of diverse mechanisms. In contrast to miRNAs, which have been extensively studied and have wellunderstood functions in gene regulation, lncRNAs are not well studied or characterized.
MICRORNAS BIOGENESIS
miRNAs are evolutionarily conserved and are located either within the introns or exons of proteincoding genes (70%) or in intergenic regions (30%). Most intronic and exonic miRNAs are derived from their host genes, which suggests that they are transcribed concurrently with their host transcripts. Transcripts containing primary miRNAs (primiRNAs), which can vary from 200 nt to several kb in length, are capped with a specially modified nucleotide at the 5′-terminus and are polyadenylated with multiple adenosines at the 3′-end. Pri-miRNA is cleaved into precursor-miRNA (premiRNA: 60-70 nt in length) by the RNAse III enzyme (also known as Drosha). PremiRNA is exported from the nucleus into the cytoplasm by exportin5. In the cytoplasm, premiRNA is cleaved by another RNase III enzyme, known as Dicer, into miRNA duplexes of approximately 19-22 nt in length. One miRNA duplex is then recruited into the RNAinduced silencing complex and functions to recognize complementary sites within the target messenger RNA (mRNA), thereby regulating translation through mRNA cleavage, degradation, or transcriptional repression [12] .
MICRORNA PROFILING STUDIES IN BLADDER CANCER
miRNA expression profiling by arraybased and poly merase chain reaction (PCR)based methods is not commonly used because these methods only allow for identification of a limited number of known miRNAs. The rapid development of highthroughput, deep sequencing (DS) technology has provided novel information regarding the functions and features of miRNAs. Han et al. [13] first reported miRNA profiling in BC by using an Illumina Genome Analyzer IIX in 2011. Soon thereafter, five studies used DS technology to establish the miRNA profiles of clinical BC samples [14 18 ]. To date, the largest DS study on BC is a comprehensive investigation by The Cancer Genome Atlas Research Network [18] . Tissues from 131 patients with highgrade MIBC were analyzed by RNA sequencing together with 118 blood samples from the same individuals and 23 adjacent histologically proven normal tissues. The aim of the project was to carry out genetic and epigenetic characterization of the molecular landscape of highgrade MIBC. In our studies, we conducted miRNA profiling by use of both PCR based methods and DS technology [17, 19] . When comparing our 2 studies, the altered expression of miRNAs detected by DS technology was very similar to the results of PCR based methods. In addition, a considerable number of novel miRNAs have been reported by some studies [13, 14, 17] . Therefore, this analysis supports that DS technology is superior to previously used methods. Although PCRbased and DS profiles are not comparable from a quantitative point of view, sequencing approaches should provide substantial improvements to transcriptome analyses.
MOLECULAR TARGETS OF MICRORNAS IN BLADDER CANCER

Features of miRNA studies in BC
Growing evidence has demonstrated that aberrantly expressed miRNAs can act as oncogenic miRNAs (onco miRNAs) or tumorsuppressive miRNAs (TSmiRNAs) in BC [12, 20] . Because miRNAs can construct miRNAtarget gene networks that contribute to tumor initiation, survival, and invasion, many investigators have focused on the genes targeted by aberrantly expressed miRNAs in BC in comparison with normal bladder epithelium. In terms of miRNA analysis, luciferasereporter assays are useful for confirming the direct binding of miRNAs to the specific 3′-untranslated region of the mRNA representing the target gene. Hence, we have summarized the miRNA studies in BC for which the target genes were validated by luciferase reporter assays. To date, we have identified 78 studies that satisfied our criteria (Tables 1 and 2 ). As shown in Table 1 , several TSmiRNAs, including miR1, miR16, miR24, miR 101, miR125b, miR129, and miR133a, have been shown to be located on different chromosomal regions but to have common sequences in their mature miRNAs. This suggests that the expression of these TSmiRNAs may be maintained by another genomic region, even though one region may be functionally disordered because of methylation, deletion, or mutation. This type of backup system is thought to have important roles in protecting normal cells f rom carcinogenesis. www.icurology.org miRNAs in bladder cancer 
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The miRNAs in Table 1 are listed in order of miRNA number, and the validated target genes are indicated. Interestingly, among the 54 miRNAs examined, 45 were downregulated, whereas 9 were upregulated. In our experience, we often encountered difficulties with the use of antimiRNAs in in vitro studies; however, miRNA restoration systems using miRNA transfection are well established and commercially available. Accordingly, the latter system may be easier to use to examine the potential tumorsuppressive roles of the downregulated miRNAs.
miRNAs have been shown to regulate target gene ex pression. Several miRNAs and their targets have been identified in BC (Table 2 ). Among the 61 target genes examined, the expression levels in clinical BC specimens compared with the levels in normal bladder epithelium were validated for 40 genes. The downregulation of several miRNAs, including miR1, miR133a, miR145, miR195, and the miR200 family, has been reported, and these miRNAs have been shown to be involved in crucial cellular processes, such as the epithelialmesenchymal transition (EMT), cell cycle, apoptosis, and cancer signaling pathways. TSmiRNAs and their target genes were classif ied into functional annotations by using the Kyoto Encyclopedia of Genes and Genomes pathways (Table 2 ).
Clustered miRNAs
Several miRNAs are located in close proximity (within 10 kbp) in the same genomic region; this is called a miRNA cluster. Because of their simultaneous expression, common target genes of miRNAs within a cluster may be important for tumor biology. For example, miR145 forms a cluster with miR143 on chromosome 5q32, and these clustered miRNAs are regulated by a common promoter [21] . Research indicates that both miR145 and miR143 are frequently downregulated in a broad range of cancers, including BC.
Villadsen et al. [22] suggested that SERPINE1 is a direct target of both miR145 and miR143; this was the first report of an miRNA cluster targeting the same mRNA in BC. Importantly, miR145 has been implicated in the p53 regulatory network in human malignancies [23] . p53 transcriptionally induces the expression of miR145 by interaction with a potential p53 response element in the miR145 promoter; moreover, MYC is directly repressed by miR145. Additionally, Chiyomaru et al. [24] found direct binding of the miR23b/27b cluster with EGFR/MET, and Itesako et al. [17] found direct binding of the miR195/497 cluster with BIRC5, which encodes survivin.
Cell cycle/apoptosis-related genes
Avoidance of apoptosis and cell cycle acceleration are required for cancer cells to escape cell death. BCL2L2, a member of the BCL2 family, can promote cell survival by inhibiting the intrinsic pathway of apoptosis. In contrast, BIRC5 (survivin ) is a key member of the inhibitor of apoptosis protein family. Several TSmiRNAs induce apoptosis through targeting BCL2L2 (miR133b, miR203) and BIRC5 (miR195, miR203, miR497). Upregulation of miR129 may be involved in avoidance of apoptosis through direct targeting of SOX4 and GALNT1, which are involved in transcription and protein expression, respectively [25] . One important pathway is the sequential activation of caspases, which have a central role in the execution of cell apoptosis. miR1 is downregulated in both clinical BC tissues and cultured BC cells and has been shown to induce apoptosis by increasing the activity of caspases 3 and 7 through direct targeting of the apoptosis inhibitor SRSF9 [26] . Additionally, CASP2 (caspase 2) is directly targeted by an oncomiRNA, miR706 [27] .
Several miRNAs have been shown to control the cell cycle through their target genes. Matsushita et al. [28] first 
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reported that cellcyclerelated genes, such as CCNE1/2, CDC25A, and PKMYT1, are directly regulated by miR144 5p. CDC25A is also regulated by miR449a, and CDK4 and CDK6 are regulated by miR1243p, miR195, miR29c, miR 230c, and miR449a, inducing G 1 phase arrest. Interestingly, miR96, which is upregulated in BC, directly binds to CDKN1A (p21), a wellknown tumorsuppressive gene [29] . Moreover, miR125b and miR200c target the oncogene E2F3, which is critical for the G 1 /S transition and is overexpressed in most highgrade BCs [30, 31] . Inoguchi et al. [32] found that miR24 regulates FOXM1, which is critical for mediating cell cycle progression proteins, such as Aurora B, cyclin B1, and CDC25B, and stimulates the expression of SKP2/CKS1, which is involved in the proteolysis of p27 kip1 and in G 1 /S progression.
EMT-related genes as targets of miRNAs in BC
We also evaluated whether the expression of the different target genes could be validated in clinical BC samples ( Table 2 ). The EMT is a key progression mechanism that is often activated during cancer invasion and metastasis and is characterized by loss of cell adhesion, repression of E cadherin expression, and increased cell mobility [33] . Members of the miR200 family are wellknown regulators of the EMT in human malignancies, including BC [34] , and some investigators have reported the functions of these miRNAs in BC [35, 36] .
FSCN1 and LASP1 are components of the filopodia and lamellipodia in various types of cells; both proteins are involved in mediating the dynamics of actin filaments and are activated during the EMT. miR133a and miR145 directly regulate FSCN1 [37] , and the miR1/133a cluster and miR218 regulate LASP1 [38] . Restoration of the expression of these miRNAs accelerates cell migration and invasion activity in vitro [37, 38] . Matrix metalloproteinases (MMPs) are calciumdependent zinccontaining endopeptidases that are capable of degrading various extracellular matrix proteins. MMPs are involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), and chemokine/cytokine inactivation. MMPs are also thought to facilitate tumor cell invasion and metastasis via the degradation of the extracellular matrix. Transforming growth factor beta1 reduces the expression level of miR 200b, which directly regulates MMP16. This then activates other MMPs (e.g., MMP2 and MMP9), growth factors, and receptors, thereby facilitating local cellular mechanisms that promote migration [39] .
Loss of expression of miR23b, miR138, and miR200c (an miR200 family member) is associated with increased expression of ZEB1, ZEB2, and ERFFI1, which facilitate the progression of the EMT [36, 40, 41] . ZEB1 and ZEB2 are known to negatively regulate E cadherin expression and are directly targeted by miR23b and miR138, whereas ERRFI1, a regulator of EGFR, is directly targeted by members of the miR200 family [36] . ZEB1 expression has been reported in 22% of clinical BC tissue specimens, but is absent f rom the bladder mucosa [42] . Expression of the miR200 family has been shown to be repressed by hypermethylation of its promoter region, and loss of miR 200c expression is significantly associated with subsequent disease progression to MIBC and poor outcomes [35] . These studies implied that many EMTrelated genes are activated through downregulation of several TSmiRNAs, and these phenomena may contribute to tumor progression of BC.
Others
Downregulated miRNAs have also been reported to target some genes related to cytokine-cytokine receptor interactions, including EGFR (miR23b, miR27b, miR133a, miR133b) [24, 43] , IGF1R (miR145) [44] , and MET (miR23b, miR27b, miR101) [24, 43] . Activation of these genes may affect downstream cancer pathways, such as mammalian target of rapamycin signaling, phosphoinositol 3kinase (PI3K)Akt signaling, and mitogenactivated protein kinase (MAPK) signaling. FGFR3, which belongs to the MAPK signaling pathway, is crucial for BC oncogenesis, and mutations in FGFR3 have been shown to accelerate proliferation in BC [45] . Downregulation of miR99a and miR100 has been shown to cause upregulation of FGFR3 expression before its mutation, which suggests that the acquisition of mutations may result from increased cell turnover [46] . The expression of AKT1 and ILK, which are involved in the AKTPI3K pathway, was shown to be repressed by the miR143/145 cluster, and proliferation is inhibited in cells transfected with these miRNAs [47, 48] . The vascular endothelial growth factor (VEGF) and WNT signaling pathways are also important for BC development, and VEGFC, FZD4, PSEN1, and WNT1 have been reported to be under the control of several TSmiRNAs [17, 4952] .
MICRORNAS AS TUMOR MARKERS IN BLADDER CANCER
miRNAs as diagnostic markers for BC detection
Many studies have investigated miRNA expression by quantitative realtime PCR of clinical BC specimens [20] . In this review, we focus on studies in which the investigators evaluated diagnostic accuracy by use of receiveroperator curve analyses of the sensitivity and specificity of specific miRNAs in comparison with normal bladder epithelium. We found 18 studies that satisfied our criteria (Table 3 ). In 2009, Ichimi et al. [19] first evaluated the expression of six miRNAs in tissues as diagnostic markers to distinguish BC (n=104) from nonBC (n=31).
There is a pressing need for highly accurate, noninvasive tests for BC diagnosis. The standard procedures for BC diagnosis and the followup for patients depend on urinary cytology and cystoscopy. Urinary cytology is a reliable urine marker for BC diagnosis because of its high specificity (90%-95%). However, this method has low sensitivity (30%-40%), and patients are forced to undergo a painful cystoscopic procedure to confirm the diagnosis. A number of noninvasive urine tests, such as bladder tumor antigen and NMP22, have been developed; however, their diagnostic specificities are inferior to that of urinary cytology tests, and these methods have failed to meet clinical expectations. Therefore, quantitative changes in miRNAs in urine, blood, and tissues are the primary focus in the search for new markers. miRNAs are detectable in urine with pelleted or cellfree urine samples. Hanke et al. [53] evaluated miR126 expression in whole urine samples and showed that this miRNA had a sensitivity of 72% and specificity of 82% when used as a diagnostic marker, even though the sample size in their study was small. Yamada et al. [54] also found that miR96 detection in the urine including the pellet was a useful diagnostic marker, with a sensitivity of 71.8% and a specificity of 89.2%. Shimizu et al. [55] uniquely reported good sensitivity of 81% and good specificity of 89% by testing a methylation panel of miR93/miR1242/miR1243/ miR137. In terms of miRNA detection in cellfree urine [56 60] , several studies have shown that this method provides moderate sensitivity and specificity for distinguishing BC from nonBC but that the results are inferior to those from studies using whole urine samples [5355, 61, 62] . In blood tests, Jiang et al. [63] showed dramatic results (sensitivity of 90% and specificity of 90%) using a panel study of miR15b5p/ miR27a3p/miR30a5p/miR148b3p/miR152/miR31873p.
miRNAs for predicting prognosis in patients with BC
Many retrospective studies have suggested that the expression of specific miRNAs in BC specimens may be a good prognostic marker predicting overall survival, disease free survival, recurrencefree survival, or progressionfree survival, as outlined in Table 4 . Moreover, several reports analyzing urine and blood samples have shown that miR 200, miR214, and miR31873p levels are good prognostic markers in the blood [57, 60, 63, 64] . Surprisingly, miR203, miR 214, miR152, and miR31873p were shown to be independent markers predicting overall survival, progressionf ree survival, or recurrencefree survival in multivariate studies [6365] . Unfortunately, no prospective studies have been performed to date. Thus, additional large, prospective studies are needed for the clinical application of miRNA assays for diagnostic and prognostic purposes in BC.
MICRORNAS AS A TREATMENT MODAL-ITY IN BLADDER CANCER
Some TSmiRNAs have been transfected into BC cell lines by using plasmid/virus vectors, followed by subcutaneous injection of the transfected cells into nude mice [27, 66, 67] . Significant inhibition of tumor growth [27, 67] and metastasis [66] was observed. Yu et al. [66] found that the CD44 gene was a direct target of miR34a and that the proapoptotic role of miR34a may be mediated primarily through regulation of CD44, which functions to promote metastasis and angiogenesis. Xu et al. [68] demonstrated that miR100 miRNAs in bladder cancer transfected BC cells exhibited significant growth inhibition in an intravesical orthotopic BC model. In terms of onco miRNAs, miR10b and miR155transfected BC xenografts exhibited significantly increased growth in comparison with controls [69, 70] . Inamoto et al. [71] tested the anticancer effects of intravesical injection of miR145 by using cationic liposomes (Lipofectamine RNAiMAX, Thermo Fisher Scientific, Waltham, MA, USA) in an intravesical orthotopic BC model. They achieved adequate anticancer effects after intravesical administration of miR145. These miRNAs are promising candidate miRNAs that may be useful for clinical applications in the future.
FUTURE PERSPECTIVES
Many studies have examined the roles of miRNAs in human malignancies, including BC. However, the majority of miRNA studies have focused on candidate gene A growing body of evidence has shown that miRNAs have great potential for clinical use as new diagnostic biomarkers. However, detection of single miRNAs in urine samples will not be superior to current urinary cytology tests because of the relatively low diagnostic specificity of such analyses. Some recent studies have attempted to improve the diagnostic specificity of miRNA detection by using a panel of multiple miRNAs [55, 56, 61, 63] . It will be important to select optimal combinations of miRNAs and to perform prospective translational studies in outpatients to validate such miRNA panels.
Moreover, recent studies have shown that some miRNAs control the activity of major cancerrelated signal ing molecules. Thus, identification of aberrant miRNA expre ssion and oncogenic or tumorsuppressive molecular targets of miRNAs is necessary for the clinical development of novel cancer therapeutics. Because many TSmiRNAs and their target oncogenes are components of complex molecular networks, treatment with multiple miRNAs may provide stronger anticancer effects than treatment with a single miRNA. In an interesting study by Liu et al. [72] , new vectors, termed "miRNAmowers," that contained the entire sequence of the oncomiR18396182 cluster were constructed. Transfection of the miRNAmowers strongly inhibited cell growth and migration and induced apoptosis in vitro, 
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suggesting the usef ulness of targeting multiple onco miRNAs. However, no studies have yet reported successful results for intravenous administration of TSmiRNAs in the induction of anticancer effects in vivo. The development of an adequate drug delivery system for TSmiRNAs is needed; otherwise, it will be difficult to determine the value of miRNAs as a therapeutic modality.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest to disclose.
